A detailed history of Great Valley Advisor Group, Inc. transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Great Valley Advisor Group, Inc. holds 442 shares of REGN stock, worth $314,880. This represents 0.01% of its overall portfolio holdings.

Number of Shares
442
Previous 421 4.99%
Holding current value
$314,880
Previous $442,000 4.98%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$1024.09 - $1201.76 $21,505 - $25,236
21 Added 4.99%
442 $464,000
Q2 2024

Jul 16, 2024

SELL
$883.2 - $1071.19 $205,785 - $249,587
-233 Reduced 35.63%
421 $442,000
Q1 2024

May 03, 2024

BUY
$902.69 - $993.35 $1,805 - $1,986
2 Added 0.31%
654 $629,000
Q4 2023

Feb 05, 2024

SELL
$775.18 - $881.7 $389,140 - $442,613
-502 Reduced 43.5%
652 $572,000
Q3 2023

Nov 06, 2023

BUY
$692.45 - $844.37 $150,954 - $184,072
218 Added 23.29%
1,154 $949,000
Q2 2023

Aug 10, 2023

BUY
$700.03 - $830.35 $120,405 - $142,820
172 Added 22.51%
936 $672,000
Q1 2023

May 02, 2023

BUY
$680.49 - $826.97 $519,894 - $631,805
764 New
764 $627,000
Q4 2021

Feb 10, 2022

SELL
$543.48 - $670.97 $295,109 - $364,336
-543 Closed
0 $0
Q3 2021

Oct 14, 2021

BUY
$574.03 - $680.96 $311,698 - $369,761
543 New
543 $329,000
Q4 2020

Jan 29, 2021

SELL
$478.3 - $607.98 $199,451 - $253,527
-417 Closed
0 $0
Q3 2020

Oct 21, 2020

BUY
$544.75 - $658.21 $29,416 - $35,543
54 Added 14.88%
417 $233,000
Q2 2020

Jul 31, 2020

BUY
$493.32 - $643.92 $179,075 - $233,742
363 New
363 $227,000

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $76.4B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Great Valley Advisor Group, Inc. Portfolio

Follow Great Valley Advisor Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Great Valley Advisor Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Great Valley Advisor Group, Inc. with notifications on news.